NCT03877848View on ClinicalTrials.gov

EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

CompletedOBSERVATIONAL
Enrollment

319

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
Coronary Stenosis
Interventions
DEVICE

Percutaneous Coronary Intervention (PCI)

Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.

Trial Locations (1)

Unknown

Medinol LTD, Tel Aviv

Sponsors

Lead Sponsor

Medinol Ltd.
All Listed Sponsors
lead

Medinol Ltd.

INDUSTRY

NCT03877848 - EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study | Biotech Hunter | Biotech Hunter